Budoprutug Phase 2 shows immunologic remission pMN
Climb Bio presented positive Phase 2 PrisMN data for budoprutug, showing B-cell depletion at 200 mg and supportive MCD case study results, while maintaining a neutral financial stance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed